• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue

    Simply Wall St·08/09/2026 11:40:24
    Listen to the news
    • Roivant Sciences Ltd. reported first-quarter 2026 results for the period ended June 30, showing sales of US$1.44 million versus US$2.17 million a year earlier and a net loss of US$189.84 million compared with US$223.36 million.
    • While revenue slipped, the narrowing net loss and lower basic loss per share from continuing operations may influence how investors assess Roivant’s progress on efficiency and cost control.
    • We’ll now examine how the reduced quarterly sales but narrower net loss reshape Roivant Sciences’ existing investment narrative and future expectations.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Roivant Sciences Investment Narrative Recap

    To own Roivant Sciences, you need to believe its late stage immunology pipeline can eventually turn today’s small sales base into meaningful, recurring product revenue. The latest quarter’s lower revenue but narrower net loss does not appear to change the key short term catalyst, which is upcoming clinical and regulatory milestones, or the biggest risk, which remains potential trial setbacks and the ongoing cash demands of R&D.

    The most relevant recent announcement is Roivant’s April 2026 update on brepocitinib and other programs, which highlighted multiple Phase 2b/3 and Phase 3 efforts across dermatomyositis and noninfectious uveitis. Against the backdrop of modest Q1 sales and a large net loss, investors may view progress in these late stage trials as increasingly important for validating the long term thesis and justifying continued high R&D spending.

    Yet the real risk investors should be aware of is how prolonged high R&D costs and potential trial delays could...

    Read the full narrative on Roivant Sciences (it's free!)

    Roivant Sciences’ narrative projects $1.8 billion revenue and $337.8 million earnings by 2029.

    Uncover how Roivant Sciences' forecasts yield a $39.04 fair value, a 7% upside to its current price.

    Exploring Other Perspectives

    ROIV 1-Year Stock Price Chart
    ROIV 1-Year Stock Price Chart

    Some analysts were far more optimistic before this update, assuming revenue could reach about US$4.2 billion and earnings US$1.2 billion by 2029, so you should expect that views on Roivant’s risk reward trade off may shift as this latest loss and modest US$1.44 million in quarterly sales are digested.

    Explore 5 other fair value estimates on Roivant Sciences - why the stock might be worth less than half the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Roivant Sciences research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Roivant Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Roivant Sciences' overall financial health at a glance.

    Contemplating Other Strategies?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.